DermaSensor Study Results For Skin Cancer Detection Device Performance Across Skin Tones Of Over 1,000 Patients
Forty-eight skin cancers were detected in subjects with Fitzpatrick skin type IV-VI.
- Forty-eight skin cancers were detected in subjects with Fitzpatrick skin type IV-VI.
- Importantly, there was minimal variation in device sensitivity, specificity, and Area under the Receiver Operating Characteristic Curve (AUROC) when comparing patients in the two FST subgroups to each other and to overall study results.
- "Our mission at DermaSensor has always been to provide access to tools to aid in skin cancer evaluations”, said Cody Simmons, CEO of DermaSensor.
- “The results from the DERM-SUCCESS study suggest that our ESS technology performs comparably regardless of skin type, which could improve providers’ ability to assess lesions on all patients and thus increase equitable access to effective skin cancer exams.”